FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular the use of an antibody neutralizing NKG2A activity is proposed for the treatment of cancer in a human individual that poorly (weakly) responds to the treatment with an antibody neutralizing PD-1. A method is proposed for the identification of an individual with high probability of no response to the treatment with the antibody neutralizing PD-1. A method for the treatment of cancer is also proposed, using a combination of antibodies neutralizing NKG2A and PD-1 activity.
EFFECT: obtaining a method for the treatment of cancer.
24 cl, 8 dwg, 3 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | 2018 |
|
RU2781116C1 |
| CD73 BLOCKING ANTIBODIES | 2020 |
|
RU2819204C2 |
| NK-CELL ACTIVATING FUSED PROTEIN, NK-CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2018 |
|
RU2740438C1 |
| MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USE | 2020 |
|
RU2815388C2 |
| ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137 | 2019 |
|
RU2826084C2 |
| COMPOSITIONS AND METHODS FOR MODULATING THE TRANSMISSION OF A LAIR SIGNAL | 2017 |
|
RU2757394C2 |
| CD30XCD16 ANTIBODY COMBINATION FOR THERAPY WITH PD-1 ANTAGONIST | 2016 |
|
RU2761352C2 |
| SOLUBLE UNIVERSAL REINFORCING ADCC SYNTHETIC FUSED GENE, PEPTIDE TECHNOLOGY AND USE THEREOF | 2015 |
|
RU2725807C2 |
